EntreMed (CASI) Earns Daily Coverage Optimism Rating of 0.10

Press coverage about EntreMed (NASDAQ:CASI) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EntreMed earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.6308155390736 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Shares of CASI stock opened at $7.01 on Friday. EntreMed has a 12-month low of $0.91 and a 12-month high of $7.59. The firm has a market cap of $489.80, a PE ratio of -38.94 and a beta of 0.90.

EntreMed (NASDAQ:CASI) last issued its quarterly earnings data on Thursday, March 29th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.06). research analysts expect that EntreMed will post -0.13 EPS for the current fiscal year.

Several equities research analysts have recently issued reports on CASI shares. BidaskClub downgraded shares of EntreMed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th. HC Wainwright reissued a “buy” rating and set a $4.50 price objective on shares of EntreMed in a research report on Monday, January 29th. Finally, ValuEngine raised shares of EntreMed from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.

In other EntreMed news, Director Wei-Wu He bought 3,086,419 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The stock was acquired at an average price of $3.24 per share, with a total value of $9,999,997.56. Following the completion of the transaction, the director now owns 847,527 shares in the company, valued at $2,745,987.48. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder China Growth Fund Idg-Accel II bought 3,086,418 shares of the firm’s stock in a transaction that occurred on Wednesday, March 21st. The stock was acquired at an average cost of $3.19 per share, with a total value of $9,845,673.42. The disclosure for this purchase can be found here. 24.52% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3339918/entremed-casi-earns-daily-coverage-optimism-rating-of-0-10.html.

About EntreMed

CASI Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma.

Insider Buying and Selling by Quarter for EntreMed (NASDAQ:CASI)

Receive News & Ratings for EntreMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EntreMed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ProAssurance  Earns Hold Rating from Sandler O’Neill
ProAssurance Earns Hold Rating from Sandler O’Neill
Incyte  Stock Rating Reaffirmed by Guggenheim
Incyte Stock Rating Reaffirmed by Guggenheim
Hess  Given New $52.54 Price Target at Bank of America
Hess Given New $52.54 Price Target at Bank of America
S&w Seed’s  “Buy” Rating Reiterated at Noble Financial
S&w Seed’s “Buy” Rating Reiterated at Noble Financial
CME Group  Stock Rating Upgraded by Zacks Investment Research
CME Group Stock Rating Upgraded by Zacks Investment Research
Critical Comparison: Sealed Air  & Celanese
Critical Comparison: Sealed Air & Celanese


Leave a Reply

© 2006-2018 Ticker Report. Google+.